NEW! Search CPT Codes in the Main Search Bar: To check prior authorization requirements, please use the Search Bar at the very top of the page. It's always available, so you can check codes from anywhere on the site!

Published Date: 2025-07-22

Medetomidine: What Providers Need to Know

Medetomidine, a synthetic alpha-2 adrenoreceptor agonist used as a veterinary sedative and analgesic, has been increasingly found as an adulterant in Pennsylvania's illicit opioid supply. More potent than xylazine, medetomidine prevalence has surged, becoming the most common adulterant in Philadelphia, with trends suggesting statewide spread.

Providers should be aware of medetomidine's effects: deep and prolonged sedation, miosis, bradycardia, initial hypertension followed by hypotension, and bradypnea.

A significant concern is the severe and atypical withdrawal syndrome associated with medetomidine, characterized by:

Rapid Onset: Severe withdrawal presents by 12-24 hours since last use and symptoms can progress from mild to critical within hours.
Severe Nausea and Vomiting
Tachycardia (~170s) and Hypertension (~170-230s/120-140s)
Excessive Diaphoresis
Anxiety and Agitation
Tremor and Myoclonic Jerks that can look like seizures (but unlikely to be true seizure activity)
Waxing and Waning Hypoactive Encephalopathy: Described as somnolence or stupor and may be incorrectly interpreted as uncooperative behavior.
Tremor: Described as teeth chattering, facial twitching, body shaking, and rigor.

Treatment Considerations for Medetomidine Withdrawal

Management requires a low threshold for transferring patients to higher levels of care, potentially requiring admission to critical care.
The Clinical Opioid Withdrawal Scale may be unreliable due to encephalopathy.
Avoid use of benzodiazepines early in treatment unless concurrent benzodiazepine/alcohol withdrawal is suspected.
Clonidine or guanfacine can manage mild to moderate symptoms. Severe cases or those with the inability to tolerate oral intake may require dexmedetomidine infusions.
Aggressive management of opioid withdrawal with full opioid agonists, including considering IV methadone or buprenorphine, is crucial.
Supportive measures include IV fluids, electrolyte replacement, careful monitoring of aggressive antiemetic treatment (risk of QTc prolongation), antihypertensives, and the consideration of ketamine for co-occurring pain.

To learn more, watch this recorded webinar or review this Health Alert in detail.

References: